It Kills That: Cramer Won’t Recommend Pfizer 7% Yield
Jim Cramer declines to back Pfizer despite its 7% dividend, arguing the growth case isn’t clear. Pfizer sits near a 5...
Compare index fund performance year by year to detect stability, volatility, and opportunities for strategic adjustments.
25,004 articlesJim Cramer declines to back Pfizer despite its 7% dividend, arguing the growth case isn’t clear. Pfizer sits near a 5...
Micron stock has captured attention with big moves and big questions. This guide breaks down whether now is the ultim...
IBM slumped 22% in early trading on a preliminary Q2 miss, igniting a wider tech sector selloff as analysts weigh AI ...
Oracle is at a crossroads: AI-enabled cloud growth and savvy capital management could unlock significant upside. Here...
As Iran escalates into conflict 2.0 and mortgage rates linger near the sixes, the housing market faces new tests. Thi...
Want a fabulous kid’s birthday party without blowing the budget? This guide breaks down practical, doable steps—from ...
After more than a month of walkouts, the york nurses union wins a tentative contract with NewYork-Presbyterian that i...
C2 Financial announced a nationwide expansion to reclaim its No. 1 wholesale ranking. The plan centers on AI upgrades...
A wave of new analyst calls on Thursday centers on Alcon, First Solar, Five Below, Joby Aviation, Spotify, Trade Desk...
Fed minutes reveal a widening rift among policymakers: while the Fed kept rates steady, some officials signaled possi...
Interactive Brokers clients favored Nvidia after its record quarter, purchasing the stock as it pulled back from the ...
A new AI risk assessment shows programmers face high displacement risk, upending traditional SaaS models and pressuri...